Bruker (NASDAQ:BRKR) Earns Buy Rating from Analysts at Rothschild & Co Redburn

Equities research analysts at Rothschild & Co Redburn assumed coverage on shares of Bruker (NASDAQ:BRKR) in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $60.00 price target on the medical research company’s stock. Rothschild & Co Redburn’s price target would suggest a potential upside of 38.28% from the stock’s current price.

BRKR has been the subject of a number of other research reports. Citigroup decreased their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. Cowen reiterated a “hold” rating on shares of Bruker in a research note on Tuesday, November 4th. UBS Group increased their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Bruker in a report on Thursday, November 13th. Finally, Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $49.36.

Bruker Stock Performance

Shares of NASDAQ:BRKR opened at $43.39 on Thursday. The firm’s 50 day simple moving average is $36.75 and its 200 day simple moving average is $37.23. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $64.64. The company has a market capitalization of $6.59 billion, a price-to-earnings ratio of 83.44, a P/E/G ratio of 5.31 and a beta of 1.25. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. During the same period in the prior year, the business earned $0.60 EPS. Bruker’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, sell-side analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares of the company’s stock, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 27.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BRKR. Nisa Investment Advisors LLC increased its position in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the period. Huntington National Bank lifted its holdings in Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after buying an additional 645 shares during the period. Spire Wealth Management acquired a new position in Bruker during the 2nd quarter worth about $32,000. Caitong International Asset Management Co. Ltd grew its position in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.